Cephalon announced that Mayo Clinic Proceedings published data from a Phase III trial of Nuvigil (armodafinil) Tablets [C-IV] demonstrating it significantly improved wakefulness throughout the shift in patients with excessive sleepiness associated with shift work disorder.
Preliminary research in healthy men suggests that the narcolepsy drug modafinil, increasingly being used to enhance cognitive abilities, affects the activity of dopamine in the brain in a way that may create the potential for abuse and dependence, according to a study in JAMA.
Modafinil, a wake-promoting drug used to treat sleep disorders, may enhance cognition and is used off-label for the treatment of cognitive dysfunction in some psychiatric disorders, such as schizophrenia and attention-deficit/hyperactivity disorder (ADHD).
Vanda, Pharmaceuticals, Proof-of-Concept, Phase II, clinical testing, VSF-173, excessive sleepiness, maintenance of wakefulness tests, MWT, modafinil, Provigil, Nuvigil, narcolepsy, polysomnography, PSG, Mihael Polymeropoulos, shift work sleep disorder, neuro-degenerative disorders, sleep disorders, sleepiness, excessive sleepiness, problem sleepiness.
This is a 2D-barcode containing the address of our mobile site.If your mobile has a barcode reader, simply snap this bar code with the camera and launch the site.
Many companies provide barcode readers that you can install on your mobile, and all of the following are compatible with this format:
As of May 2, 2009 at 9:47 p.m. (-0500) (ET), the U.S. population
was 306,340,710. Sleep researchers estimate approximately seven percent
of the population suffers from obstructive sleep apnea. Using that
estimate, there are potentially 21,443,850 apneics in the U.S.
~~ Apnea around the world ~~
As of May 2, 2009 at 9:47 p.m. (-0500) (ET), the world population
was 6,777,286,604. Sleep researchers estimate approximately seven percent
of the population suffers from obstructive sleep apnea. Using that
estimate, there are potentially 474,410,062 apneics in the world.
